| abstract |
The use of a compound of structural formula (I):n n or a pharmaceutically acceptable salt thereof or a prodrug thereof; wherein n R¹ represents a non-aromatic azabicyclic ring system having more than 5 ring atoms selected from:n n wherein the broken line represents an optional chemical bond; n the substituents R³ and R⁴ may be present at any position, including the point of attachment to the pyridine ring, and independently represent hydrogen, C₁₋₄ alkyl, halo, C₁₋₄ alkoxy, hydroxy, carboxy or C₁₋₄ alkoxycarbonyl; or R³ and R⁴ together represent carbonyl; and n R⁵represents hydrogen or C₁₋₄ alkyl; n provided that R¹ is attached to the pyridine ring other than at the 2′-carbon position of R¹; and n R² and R¹¹ independently represent hydrogen, halo, -CF₃, -OR⁶, -NR⁶R⁷, -CN, -COR⁸, C₁₋₈ alkyl or C₂₋₈ alkenyl; wherein R⁶ is hydrogen or C₁₋₆ alkyl; R⁷ is hydrogen or C₁₋₆ alkyl; and R⁸ represents -OR⁶ or -NR⁶R⁷; other than 3-hydroxy-3-(2-pyridinyl)-1-azabicyclo[2.2.2]-octane and 3-(2-pyridinyl)-1-azabicyclo[2.2.2]oct-2-ene; nfor the manufacture of a medicament for treating glaucoma and/or for reducing intraocular pressure. |